ストックスクリーナーアプリを入手
3.68
0.18%
0.02
前日終値:
$3.66
開ける：
$3.6
24時間の取引高:
309.63K
Relative Volume:
0.46
時価総額：
$226.37M
収益：
-
当期純損益:
$-73.79M
株価収益率:
-2.00
EPS:
-1.84
ネットキャッシュフロー:
$-77.44M
1週間 パフォーマンス:
-4.27%
1か月 パフォーマンス:
+78.85%
6か月 パフォーマンス:
+292.60%
1年 パフォーマンス:
+11.11%
1日の値動き範囲:
$3.56
$3.82
1週間の範囲:
$3.1501
$3.8851
52週間の値動き範囲:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
PYXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.65 | 200.32M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.54 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
486.93 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.43 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
830.00 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.03 | 34.11B | 398.11M | -1.03B | -868.57M | -5.7032 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Will Pyxis Oncology Inc. stock continue upward momentumEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
How risky is Pyxis Oncology Inc. stock nowJuly 2025 Decliners & Breakout Confirmation Alerts - newser.com
Why Pyxis Oncology Inc. stock is a value investor pickIPO Watch & Weekly High Return Opportunities - newser.com
Will Pyxis Oncology Inc. stock deliver better than expected guidanceSwing Trade & Proven Capital Preservation Tips - newser.com
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics - Yahoo Finance
Strategies to average down on Pyxis Oncology Inc.Chart Signals & Reliable Price Action Trade Plans - newser.com
What makes Pyxis Oncology Inc. stock attractive to growth fundsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery - Yahoo Finance
Pyxis Oncology to Present Translational Data and Key - GlobeNewswire
ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan
Smart tools for monitoring Pyxis Oncology Inc.’s price action2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Can Pyxis Oncology Inc. stock beat analyst upgradesTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Full technical analysis of Pyxis Oncology Inc. stockJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Developing predictive dashboards with Pyxis Oncology Inc. data2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com
Pyxis Oncology Gains 70%, Insider Trades Reap Benefit - 富途牛牛
Pyxis Oncology (NASDAQ:PYXS) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Will Pyxis Oncology Inc. see short term momentumVolume Spike & Pattern Based Trade Signal System - newser.com
Is Pyxis Oncology Inc. stock undervalued vs historical averages2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Is Pyxis Oncology Inc. stock a top pick in earnings seasonRate Cut & AI Enhanced Trading Signals - newser.com
Real time pattern detection on Pyxis Oncology Inc. stockMarket Growth Report & Community Consensus Picks - newser.com
Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025 - MarketScreener
Pyxis Oncology appoints Alex Kane as SVP of investor relations By Investing.com - Investing.com Australia
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Quiver Quantitative
Pyxis Oncology appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - MarketScreener
Volume spikes in Pyxis Oncology Inc. stock – what they mean2025 Support & Resistance & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Pyxis Oncology Inc.’s future2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
How institutional ownership impacts Pyxis Oncology Inc. stockMarket Sentiment Review & Daily Momentum Trading Reports - newser.com
What to do if you’re stuck in Pyxis Oncology Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - newser.com
Sector ETF performance correlation with Pyxis Oncology Inc.2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Pyxis Oncology Inc.July 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
3.27%
1.04%
大文字化:
|
ボリューム (24 時間):